STgen Bio announced on the 13th that it has signed a contract for contract manufacturing organization (CMO) services worth 9.8 billion won. STgen Bio is a CMO specialist company of the Dong-A Socio Group.
This represents 16.78% of the company's recent revenue. The client and product names will not be disclosed due to confidentiality agreements. The contract period is from June this year until May 2028, for a duration of three years.
The company offers a variety of production services, including active pharmaceutical ingredients (DS), finished pharmaceuticals (DP), and commercial quantities. Its production facilities have passed inspections from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in one go, based on advanced capabilities. It has received good manufacturing practice (GMP) approvals from regulatory authorities in eight countries, including the United Kingdom, Thailand, and Turkey.
An official from STgen Bio noted, 'We plan to secure strategic global partners based on our advanced DS and DP systems and establish a service platform encompassing all areas of CMO.'